Chronic hepatitis C virus (HCV) infection is a serious public health problem. Globally, over 170 million persons are infected and suffer from HCV infection, cirrhosis, and hepatocellular carcinoma. HCV infection is among the leading causes of death in the United States. Recently, there have been newer, direct-acting antiviral agents approved by the US Food and Drug Administration for treatment of HCV for genotypes 1-4. The aim of this study is to evaluate the clinical efficacy, pharmacologic properties, and safety profiles from clinical trials and the costs associated with the new antiviral regimens, including sofosbuvir, simeprevir, and ledipasvir/sofosbuvir.
INTRODUCTION
Chronic hepatitis C virus (HCV) infection is a serious public health problem. Over 170 million people worldwide are estimated to be infected 1 and suffer from chronic hepatitis C (CHC), high rates of cirrhosis, and end-stage liver disease, and have an increased risk for hepatocellular carcinoma (HCC). 2 In the United States, approximately 4 million people are infected with CHC, which is the leading reason for liver transplantation. 1, 3 The prevalence of people living with CHC does not include individuals who are institutionalized, incarcerated, or homeless in the US, because the estimates are derived from the National Health and Nutrition Examination Survey. Therefore, the statistics may underestimate the actual number of infected Americans. An expanded prevalence study reported between 5 and 7 million persons are actually infected in the US. [3] [4] [5] Early treatment of HCV using pegylated interferon alfa (PegIFN) and ribavirin (RBV) showed limited efficacy with a side effect profile that was intolerable to many infected patients on treatment in addition to a long treatment duration of 48 weeks. The real revolution in the HCV treatment arsenal occurred in 2011 with the introduction of boceprevir and telaprevir, which were the first oral direct-acting antiviral (DAAs) agents and were used as adjunctive therapy with PegIFN and RBV. Triple therapy with the first-generation protease inhibitors demonstrated better efficacy than dual treatment for genotype 1-infected persons, but their use against hepatitis C was hampered by a cumbersome response-guided therapy, increased pill burden, drugdrug interactions, low barriers to resistance, and significant adverse effects. [6] [7] [8] [9] Over the past 5 years, the development of additional oral DAAs that target viral enzymes and proteins across the virus life cycle has ushered in a new era for more tolerable and effective IFN-sparing treatments.
Sofosbuvir (SOF) is the first uridine nucleotide analog inhibitor of the NS5B polymerase. Simeprevir (SMV) is a second-generation inhibitor of the NS3/4A protease. Both agents were approved by the US Food and Drug Administration (FDA) in December 2013. More recently, ledipasvir/sofosbuvir (LDV/SOF) was approved in October 2014. These 3 DAAs have higher barriers to resistance, better tolerability and safety profiles, shorter durations of treatment, and significantly improved sustained virologic response (SVR) or cure rates. SVR became the benchmark for successful therapy and is still defined as HCV becoming undetectable in the blood during treatment and remaining so 24 weeks after the end of treatment. Historically, SVR at 24 weeks after completion of HCV treatment (SVR24) was used as a key response measure in clinical trials. However, recent trials investigating the efficacy of new DAAs used SVR at 12 weeks after treatment (SVR12) because of their higher efficacy rates within a shorter treatment duration. The chance of relapse after achieving SVR12 is < 1%. 10 Recent phase 3 trials data showed that undetectable HCV RNA at 12 weeks after treatment is highly reliable for prediction of overall SVR. SOFOSBUVIR SOF (Sovaldi; Gilead Sciences, Inc.) was approved by the FDA as a 400 mg once daily oral tablet for treatment of HCV genotype (GT) 1-4 for both treatment-naive and treatment-experienced patients. It is the first DAA approved as part of an IFN-sparing regimen for HCV treatment, particularly with regard to GT2 and GT3 patients. GT2 and GT3 patients receive SOF/RBV for a treatment course of 12 and 24 weeks, respectively. Because it is more difficult to eradicate patients with GT1 and GT4, SOF is coadministered with PegIFN/RBV for 12 weeks of therapy to achieve successful results. SOF has also been studied in patients with hepatocellular carcinoma awaiting liver transplantation. It is given at 400 mg once daily with RBV for up to 48 weeks or until the time of liver transplantation, whichever occurs first. It cannot be used as monotherapy and must be discontinued if PegIFN or RBV is discontinued as part of the combination therapy.
Pharmacology
SOF is an NS5B nucleotide polymerase inhibitor prodrug. It is activated intracellularly to a uridine triphosphate nucleotide that mimics an endogenous nucleotide, which the HCV ordinarily uses to copy itself. SOF undergoes extensive hepatic metabolism to form the pharmacologically active uridine analog triphosphate, GS-461203, which is then dephosphorylated to GS-331007. GS-331007 lacks anti-HCV activity in vitro. 11 In short, GS-461203 is substituted for the normal nucleotide, resulting in chain termination and prevention of viral replication. Fortunately, GS-461203 has limited, if any, binding affinity for human cellular DNA and RNA polymerases.
Food does not affect the absorption and antiviral effect of SOF, so it can be taken without regard to food. SOF is minimally bound to human plasma proteins (61%-65%). There are no dose adjustments recommended for SOF in patients with mild to severe hepatic impairment (Child-Pugh Class A-C).
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Intracellular metabolism of SOF bypasses the cytochrome P450 enzyme system and, therefore, no significant hepatic drug-drug interactions have been reported to date. After a single 400 mg oral dose of [ 14 C]-SOF, the majority of the drug was recovered in urine as GS-331007 (78%) and SOF (3.5%). The median terminal half-life of SOF was 0.4 hour. There is no need to adjust SOF dose in patients with any stage of renal impairment to end-stage renal disease requiring hemodialysis. 
Drug-Drug Interactions
SOF is a substrate of the P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) drug transporters. Drugs that are potent P-gp inducers (eg, rifampin, St. John's wort, carbamazepine, phenytoin, and phenobarbital) may significantly reduce the plasma concentrations of SOF, thereby reducing its therapeutic effects. Thus, the use of SOF with potent P-gp inducers is not recommended. On the contrary, SOF does not inhibit substrates of P-gp and BCRP 15 and NEUTRINO 13 multicenter trials demonstrated efficacy of SOF when it was coadministered with PegIFN/RBV for patients with GT1, 4, and 6. The trials data are summarized in Table 1 .
The SOF-containing regimens and duration of treatment of 12 or 24 weeks will vary according to the individual's genotype and degree of liver disease ( Table 2 ). 
Safety and Tolerability
Side effects commonly reported from SOF and RBV use include headache, nausea, and fatigue. Anemia was primarily associated with RBV. The active metabolite of SOF (GS-461203) does not inhibit human DNA and RNA polymerases or the mitochondrial RNA polymerase, which results in a favorable safety and side effect profile.
11,16
Resistance SOF has a high barrier to resistance. There were no treatment-emergent resistance events reported in the clinical trials. Study participants who had relapsed from SOF-containing regimens did not show the presence of the signature Ser282Thr (S282T) HCVresistance mutation. In vitro studies showed that S282T variants have reduced susceptibility to SOF.
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SIMEPREVIR SMV (Olysio; Janssen Therapeutics), a secondgeneration NS3/4A protease inhibitor, was approved as a 150 mg oral capsule for daily administration with PegIFN/RBV for treatment-naive or treatmentexperienced GT1 patients without the Q80K mutation. SMV can be used in treatment-experienced patients, but it is not recommended in patients who have previously failed treatments containing SMV and other HCV protease inhibitors. The recommendation for treatment-naive and treatment-experienced patients without cirrhosis is 12 weeks of SMV plus PegIFN/RBV for 24 weeks. Nonresponder patients (partial and null responders) to prior HCV therapy, including those with cirrhosis, will require 12 weeks of SMV plus PegIFN/RBV for 48 weeks. SMV cannot be used as monotherapy and must be discontinued if PegIFN or RBV is discontinued.
Pharmacology SMV belongs to the macrocyclic class and contains a sulfonamide moiety. At present, there are insufficient data to exclude an association between sulfa allergy and adverse reactions with SMV use. It is a competitive, reversible, noncovalent inhibitor of viral replication and biologic activities of the NS3/4A protease. The NS3 protease plays a critical role in viral replication as it cleaves a polyprotein into additional proteins required for replication and is itself a component of the RNA replication complex.
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Pharmacokinetics SMV is orally bioavailable, reaching a maximum serum concentration (C max ) at between 4 and 6 hours. Increased C max and area under the curve (AUC) of SMV were observed when administered with food to healthy subjects compared with fasting conditions. The rate of SMV absorption was delayed by approximately 1.5 hours, but it did not affect the AUC. Mean AUC 0-24 increased by 61%-69% in the presence of food. 18 Because of the significance of the bioavailability increase, SMV should be administered with food.
SMV is extensively bound to human plasma proteins ( 99.9%), thus there is potential for its displacement when coadministered with other highly protein-bound drugs (eg, warfarin). No dose adjustments are recommended in patients with mild to moderate hepatic impairment. However, SMV is not recommended for patients with severe hepatic impairment (Child-Pugh Class C) because of significant elevated plasma concentrations of SMV, which may result in increased frequency of adverse reactions. 18 SMV is eliminated via biliary excretion. After a single oral dose of 200 mg [
14 C]-SMV was given to healthy subjects, 91% of the total radioactivity was accounted for in feces and < 1% in urine. The terminal elimination half-life of SMV in HCV-infected Safety and efficacy have not been studied in HCVinfected patients with end-stage renal disease or in those on hemodialysis.
Drug-Drug Interactions
SMV is a substrate of CYP3A, P-gp, and the organic anion-transporting polypeptide (OATP) 1B1. It is an inhibitor of P-gp, OATP1B1, and multidrug resistance-associated protein 2 (MRP2) transporters and mildly inhibits CYP1A2 activity and CYP3A4 activity. SMV is subject to drug-drug interactions with coadministration of moderate or strong inhibitors and inducers of CYP3A enzymes, resulting in significant increases or decreases in the plasma concentrations of SMV, respectively. Thus, it is recommended that SMV not be coadministered with such potent inhibitors or inducers of CYP3A (Table 3) .
Efficacy
SMV was conducted in treatment-naive and treatment-experienced HCV GT1 patients in 6 phase 3 multicenter trials: 3 in Japan and 3 in Europe and the US. FDA approval of SMV was based on clinical data from 3 international phase 3 trials conducted in Europe and the US, including QUEST-1 (with PegIFN-2a), QUEST-2 (with PegIFN-2b), and PROMISE. [19] [20] [21] Both the QUEST-1 and QUEST-2 trials were similar in study design and evaluated the efficacy of once daily SMV plus PegIFN/RBV response-guided therapy compared with placebo plus PegIFN/RBV in treatment-naive patients. The PROMISE study, which also followed the QUEST-1 study design, enrolled patients who were prior relapsers. As with the previous QUEST studies, PROMISE followed a response-guided treatment approach. The SMV plus PegIFN2a/RBV group had a higher percentage of patients who achieved SVR12 compared with placebo plus PegIFN2a/RBV (79.2% vs. 36.1%, respectively) (P ¼ .001). 21 Recommended SMV-containing regimens are summarized in Table 4 .
The efficacy of an IFN-sparing regimen consisting of SOF combined with SMV for the treatment of GT1-infected patients was further evaluated in the COSMOS study. COSMOS was a phase 2, randomized, placebo-controlled study that evaluated the efficacy of SOF plus SMV in treatment-naive and treatment-experienced GT1 noncirrhotic patients for 12 and 24 weeks (Table 5) . 22 Treatment-experienced patients included prior relapsers, partial responders, and null responders who failed IFN-based therapy. The primary efficacy endpoint was SVR12.
Safety and Tolerability
The most commonly observed adverse effects were fatigue, headache, nausea, and flulike symptoms. These occurred in both treatment and control groups and are commonly associated with PegIFN/RBV. Mild grade anemia and skin rashes were also reported from enrolled patients in both the placebo and treatment groups, but did not lead to their discontinuation from the trials. Nausea, photosensitivity, and myalgias were reported at frequencies of > 3% for those receiving SMV plus PegIFN/ RBV. 18 Furthermore, an increased frequency of photosensitivity was associated with greater exposure to SMV.
SMV-induced photosensitivity may appear as an exaggerated sunburn in areas exposed to light. This side effect may occur in the first 4 weeks of therapy, but can occur anytime during treatment. Symptoms include burning, erythema, exudates, blisters, and edema. Patients should be advised to use sunprotective measures and limit exposure to sunlight while on treatment. If a severe photosensitivity reaction develops in association with SMV use, then discontinuation of therapy is recommended and the patient should be monitored until the reaction resolves. [19] [20] [21] Reversible hyperbilirubinemia was also a common adverse event observed in a higher proportion of patients in the SMV treatment group. In vitro studies showed that SMV is an inhibitor of the bilirubin efflux transporters OATP1B1 and MRP2, suggesting a probable mechanism for the elevations of serum bilirubin observed in clinical studies and not due to hepatotoxicity. 23 There are stopping rules for SMV use, particularly when coadministered with PegIFN/RBV. Stopping rules apply to patients who have an inadequate on-treatment virologic response (HCV RNA 25 IU/mL) at weeks 4, 12, and 24, because Delavirdine, etravirine, nevirapine they are least likely to achieve SVR12. In contrast, the stopping rules do not apply when SMV is coadministered with SOF for treatment (Table 6 ).
Resistance
Point mutations within hepatitis C viral targets such as the NS3 protease are of concern as these can reduce treatment efficacy. SMV efficacy was affected by patients carrying GT1a strains with the NS3 Q80K mutation being naturally present. The resistance barrier for Q80K variants is lower, and thus leads to the emergence of additional mutations. [19] [20] [21] Q80K is a predictor of response to SMV therapy, and its presence may lead to increased treatment failures. Thus, HCV mutation screening should be considered for patients with GT1a infection prior to the initiation of SMV-containing regimens.
LEDIPASVIR/SOFOSBUVIR
In October 2014, LDV/SOF (Harvoni; Gilead Sciences) was approved by the FDA for both treatmentnaive and treatment-experienced HCV GT1 patients with or without cirrhosis. It is a fixed-dose, combination tablet consisting of an NS5A inhibitor (ledipasvir 90 mg) and an NS5B nucleotide polymerase inhibitor (SOF 400 mg) administered once daily for an 8-, 12-, or 24-week treatment course, depending on prior treatment experience and the absence or presence of cirrhosis. This combination pill does not require coadministration of RBV to achieve excellent SVR12 rates ( 94%). Similar to the mechanism of action of SOF, LDV inhibits HCV NS5A protein, which is essential for viral replication, assembly, and secretion.
Pharmacokinetics
After oral administration of LDV/SOF, the median LDV peak concentration was seen 4-4.5 hours postdose. In contrast, SOF was rapidly absorbed and the peak median plasma concentration was observed approximately 0.8-1 hour postdose. Exposure of LDV/SOF to a moderate-fat (w600 kcal) or high-fat (w1,000 kcal) meal increased SOF AUC 0-inf by 2-fold; however, it did not significantly affect SOF plasma exposure (C max ). Therefore, LDV/SOF can be administered with or without food.
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LDV is highly protein bound (> 99.8%) and is not metabolized by the CYP450 system. Rather, LDV undergoes slow oxidative metabolism via an unknown mechanism. 24 Biliary excretion of unchanged LDV is a major route of elimination, and renal excretion is a minor pathway (w1%). Approximately 87% of the radioactive dose was recovered in feces and urine after a single 90 mg oral dose of [
14 C]-LDV. The median terminal half-life of LDV after LDV/SOF administration was 47 hours.
Drug-Drug Interactions LDV and SOF are P-gp and BCRP substrates. Potent P-gp inducers (eg, rifampin and St. John's wort) may significantly decrease plasma concentrations of LDV and SOF, resulting in reduced therapeutic effects of LDV/SOF. Therefore, coadministration of LDV/ SOF with potent P-gp inducers is not recommended. In contrast, coadministration of LDV/SOF with P-gp or BCRP inhibitors can mildly increase LDV and SOF plasma concentrations, but without clinical significance. Therefore, LDV/SOF may be coadministered with P-gp or BCRP inhibitors. LDV is an inhibitor of P-gp and BCRP transporters, and may increase intestinal absorption of coadministered P-gp and BCRP substrates. Because of its high protein binding, LDV inhibitory effects on P-gp and BCRP substrates may not be clinically relevant. 24 Efficacy, Safety, and Tolerability
The efficacy and safety of LDV/SOF with or without RBV were evaluated in 3 phase 3 multicenter trials with 1,518 enrolled patients: ION-3, ION-1, and ION-2. All study patients had GT1 infection with compensated liver disease. The primary efficacy endpoint was SVR12. ION-3 was a randomized, open-label study that enrolled 647 treatment-naive, noncirrhotic patients. Patients were stratified by GT1 subtype (1a vs. 1b) and randomized in a 1:1:1 ratio to 1 of 3 treatment regimens: LDV/SOF for 8 weeks (n ¼ 215); LDV/SOF/RBV for 8 weeks (n ¼ 216); or LDV/SOF for 12 weeks (n ¼ 216). 25 The oral RBV dose administered was weight-based (1,000 mg/day if < 75 kg or 1,200 mg/day if 75 kg). Similar response rates were observed in the 3 treatment arms: 94% (LDV/SOF for 8 weeks); 93% (LDV/SOF/RBV for 8 weeks); and 95% (LDV/SOF The Journal for Nurse Practitioners -JNP Volume 11, Issue 7, July/August 2015for 12 weeks). There was no significant difference between SVR12 rates for GT1a and GT1b patients in these treatment arms (SVR12 ranged from 93% to 98%). A subanalysis showed that patients with baseline HCV RNA < 6 million IU/mL and receiving LDV/SOF for 8 weeks had slightly higher SVR12 rates compared with the other regimens. 25 Evidence from the study showed no additional benefit associated with the addition of RBV to the LDV/ SOF regimen or by extending the treatment duration to 12 weeks. The data strongly suggest that an 8-week treatment course is cost-effective and reasonable for treatment-naive patients without cirrhosis with baseline HCV RNA < 6 million IU/mL.
ION-1 was a randomized, open-label trial that evaluated LDV/SOF with or without RBV over 12-and 24-week treatment courses. The trial enrolled 865 treatment-naive HCV GT1 patients who were randomized in a 1:1:1:1 ratio to 1 of 4 treatment groups: LDV/SOF for 12 weeks (group 1, n ¼ 214); LDV/SOF/RBV for 12 weeks (group 2, n ¼ 217); LDV/SOF for 24 weeks (group 3, n ¼ 217); and LDV/SOF/RBV for 24 weeks (group 4, n ¼ 217). 26 Patients were stratified according to GT1 subtype (1a vs. 1b) and cirrhosis (presence vs. absence). All treatment groups had SVR12 rates of > 95% (group 1: 99%; group 2: 97%; group 3: 98%; group 4: 99%). Furthermore, SVR12 rates in the 4 groups ranged from 94% to 100% among patients with cirrhosis and 97% to 99% among those with GT1a infection. 26 Overall, there were no differences observed between the 12-and 24-week treatment courses, and RBV did not improve SVR rates. The most commonly reported adverse reactions were fatigue, headache, nausea, and insomnia.
The ION-2 trial design mirrored that of the ION-1 trial, wherein the efficacy and safety of LDV/ SOF with or without RBV was evaluated over a 12-or 24-week treatment course. Unlike ION-1, ION-2 enrolled treatment-experienced GT1 patients who had not achieved SVR with previous IFN-based therapies, including HCV protease inhibitor regimens. Four hundred forty patients were randomized in a 1:1:1:1 ratio to 1 of 4 treatment groups: LDV/ SOF for 12 weeks (group 1, n ¼ 109); LDV/SOF/ RBV for 12 weeks (group 2, n ¼ 111); LDV/SOF for 24 weeks (group 3, n ¼ 109); and LDV/SOF/RBV for 24 weeks (group 4, n ¼ 111). 27 Patients were stratified according to GT1 subtype (1a vs. 1b), cirrhosis (presence vs. absence), and response to previous therapy (relapse or virologic breakthrough vs. no response).
The 12-week treatment groups had high SVR12 rates (group 1: 94%; group 2: 96%). Both 24-week treatment groups had an SVR12 rate of 99%. 27 In addition, SVR12 rates were lower for patients with cirrhosis and receiving the 12-week treatment course (group 1: 86%; group 2: 82%) as compared with the respective 95% and 100% response rates in the 12-week treatment group without cirrhosis. SVR12 rates were 99%-100% in both 24-week treatment groups, including those with cirrhosis. Eleven of the 440 www.npjournal.org The Journal for Nurse Practitioners -JNPpatients (2%) had virologic relapse after the 12-week treatment course (7 patients in group 1 and 4 patients in group 2). 27 Resistance screening showed that all 11 patients had detectable NS5A-resistant variants at the time of virologic relapse. Six of the 11 patients had NS5A-resistant variants at baseline. The NS5B S282T variant, which reduces susceptibility of SOF, was not observed in the trial. The study evidence suggests that treatment-experienced patients with cirrhosis may benefit from receiving treatment for 24 weeks (Table 7) .
Aside from the clinical benefits and advantages associated with the newly approved DAAs, there are also cost considerations that may pose acquisition challenges for patients. The estimated wholesale list price of SOF is $1,000 per tablet. The cost for the SOF component in a 12-week treatment course is approximately $84,000. The total regimen cost will depend on other HCV agents used in combination with SOF. For instance, the treatment cost for GT3 patients or patients who are INF-ineligible is approximately $168,000 when on an SOF-containing regimen for 24 weeks. On the other hand, the estimated wholesale acquisition price of SMV is $790 per capsule. The cost for a 28-day supply of SMV is approximately $22,120 and a 12-week supply is $66,360. Therefore, the cost for a 12-week treatment course of SMV in combination with 24 weeks of PegIFN/RBV is approximately $87,000. In addition, the approximate cost for a 12-week course of SMV plus SOF is approximately $150,000. The wholesale acquisition price for the fixed-dose, combination pill of LDV/SOF is $1,125. The estimated costs of the LDV/SOF regimens will depend on treatment duration and will vary from $66,400 (8-week course), $94,500 (12-week course), to $189,000 (24-week course) (Table 8 ).
CONCLUSIONS
For the first time in many years, there is an option for IFN-sparing treatment of CHC with the newer DAAs. More importantly, these agents allow for a shorter duration of HCV treatment-12 to 24 weeks. These combinations offer a wide spectrum of personalizing treatment for many HCV-infected patients considered IFN-ineligible or -intolerant and for certain patient populations with advanced liver disease. It is predicted that HCV treatment will be tailored using different DAAs to achieve high tolerability and efficacy rates across all genotypes and disease stages. It remains unclear whether the new therapies for HCV will be effective against patients who are null responders to previous PegIFN/RBV therapy, who have advanced liver disease, are liver transplant recipients, or are coinfected with human immunodeficiency virus. Clinical studies are currently underway to address these concerns.
